Skip to main content

Resistance to Ibritumomab in Lymphoma

  • Book
  • © 2018

Overview

  • This book features chapters written by internationally known experts in the field
  • This book will focus on the mechanism, hematological aspects, radiological and nuclear medicine aspects and medical physics that deals with radiation dosimetry
  • This book will provide future prospects for overcoming resistance and enhancing the efficacy of Ibritumomab

Part of the book series: Resistance to Targeted Anti-Cancer Therapeutics (RTACT, volume 18)

This is a preview of subscription content, log in via an institution to check access.

Access this book

eBook USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (10 chapters)

Keywords

About this book

This volume, in discussing resistance to ibritumomab, will focus on the mechanism, hematological aspects, radiological and nuclear medicine aspects, and medical physics that deal with radiation dosimetry, and will outline future prospects for overcoming resistance and enhancing efficacy of ibritumomab.

Editors and Affiliations

  • Institute of Advanced Clinical Medicine, Kindai University Faculty of Medicine, Osaka, Japan

    Makoto Hosono

  • GIP Arronax, Nantes-Saint-Herblain, France

    Jean-François Chatal

About the editors

Makoto Hosono, MD, PhD, is a Professor of Radiology and Nuclear Medicine, Institute of Advanced Clinical Medicine, Kindai University Faculty of Medicine, Japan, and serves as a member of Committee 3, International Commission on Radiological Protection. 


Jean-François Chatal, MD, PhD, is an Emeritus Professor of Nuclear Medicine at the University of Nantes, France. He is one of the international leaders who developed radioimmunotherapy, that is, therapy using radiolabeled anti-tumor antibodies. He created and headed an INSERM  research laboratory and also initiated the installation of a cyclotron institute termed ARRONAX for the production of novel radionuclides for nuclear medicine.

Bibliographic Information

  • Book Title: Resistance to Ibritumomab in Lymphoma

  • Editors: Makoto Hosono, Jean-François Chatal

  • Series Title: Resistance to Targeted Anti-Cancer Therapeutics

  • DOI: https://doi.org/10.1007/978-3-319-78238-6

  • Publisher: Springer Cham

  • eBook Packages: Biomedical and Life Sciences, Biomedical and Life Sciences (R0)

  • Copyright Information: Springer International Publishing AG, part of Springer Nature 2018

  • Hardcover ISBN: 978-3-319-78237-9Published: 07 May 2018

  • Softcover ISBN: 978-3-030-08652-7Published: 08 January 2019

  • eBook ISBN: 978-3-319-78238-6Published: 24 April 2018

  • Series ISSN: 2196-5501

  • Series E-ISSN: 2196-551X

  • Edition Number: 1

  • Number of Pages: XIII, 158

  • Number of Illustrations: 4 b/w illustrations, 14 illustrations in colour

  • Topics: Cancer Research

Publish with us